Tailstorm Health Inc., Chandler, AZ
Is Tailstorm Health Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Tailstorm Health Inc. in Chandler, AZ, first registered Oct 23, 2019 and most recently registered Oct 9, 2026. FDA lists its last inspection as Aug 28, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Chandler, AZ
- Initial registration
- Oct 23, 2019
- Most recent registration
- Oct 9, 2026
- Last inspection
- Aug 28, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Tailstorm Health, Inc., Chandler, AZ, a 503B facility, with 5 listed actions, including 3 Form 483s and 1 untitled letter (2021 to 2026).
| Document | |||
|---|---|---|---|
| Aug 28, 2026 | Form 483 | 483 Issued 08/28/2026 | fda.gov |
| May 23, 2025 | Form 483 | 483 Issued 05/23/2025 | fda.gov |
| Oct 23, 2023 | FMD-145 letter | FMD-145 Letter Issued 10/23/2023 | Not linked by FDA |
| Jun 17, 2022 | Untitled letter | Untitled Letter Issued 06/17/2022 | FDA copy (archived) |
| Jul 21, 2021 | Form 483 | 483 Issued 07/21/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Tailstorm Health, Inc, Chandler, AZ (FEI number 3015929581), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 23, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3015929581 | 1273738 |
| Jul 21, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015929581 | 1146993 |
Form 483s FDA has published for this site
- Aug 28, 2026: Form 483 to Tailstorm Health, Inc, published Sep 29, 2026. fda.gov
- May 23, 2025: Form 483 to Tailstorm Health, Inc, published Aug 7, 2025. fda.gov
- Jul 21, 2021: Form 483 to Tailstorm Health, Inc, published Jan 7, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 14 numbered observations in all, across 3 inspections ending Jul 21, 2021 to Aug 28, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 17, 2026 to Aug 28, 2026: 5 observations
- Firm on the cover
- Tailstorm Health, Inc, 158 S Kyrene Rd, Chandler, AZ 85226-4472
- FEI number
- 3015929581
- Establishment type on the cover
- outsourcing facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087)Denver, CO 80225-008 7
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
Specifically <Redacted B4> operational/dynamic certification of the <Redacted B4> Vial Filling, Stoppering and Sealing, Machine, ISO 5 <Redacted B4> Filling Line <Redacted B4> cleanroom suite does not represent routine production operations. For example ISO 5 Filling Line was not fully assembled or inoperation, and there was one cleanroom technician outside the <Redacted B4> during dynamic nonviable particulate (NVP) monitoring. We observed up to <Redacted B4> technicians inside the ISO 7 buffer room for line ISO 5 <Redacted B4> during filling of Lidocaine 2% Injection, IO mL vial, batch 2608002. Records reviewed included: Project AZ-MVDT26l801 C-1, <Redacted B4> Cleanroom Testing and Certification, dated April 2026; and Project AZ-MVDT251301C-L Cleanroom Suite Certification, dated October 2025. All sterile drugs are manufactured on ISO 5 Filling Line <Redacted B4> personneL line setup, and production operations inside the ISO 5 <Redacted B4> are the same for aseptically filled and <Redacted B4> sterilized drugs. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
Autoclave
Qualification and routine monitoring of the <Redacted B4> equipment ID #PE00I , is deficient.
~-~~--- A There is inadequate written justification to place <Redacted B4> in the <Redacted B4> as the only process verification for routine sterilization loads. The rationale for the location of the <Redacted B4> within the <Redacted B4> is inadequate.
B . Operators do not use Biological Indicators (Bis) <Redacted B4> sterilization <Redacted B4>. The approved procedures only require Bis during <Redacted B4> qualification of <Redacted B4> loads. The most recent <Redacted B4> (qualification is documented in ) 4 .PQ.0004, Perfomance Qualification <Redacted B4> Report, <Redacted B4> PE00 1, report approved 06/19/26.
C. Your procedures only require a <Redacted B4> air removal test during <Redacted B4> qualification of the <Redacted B4> . Technicians do not perform <Redacted B4> tests before any routine <Redacted B4> cycles. There is inadequate written justification for the frequency of air removal tests. ...
Observation 3
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.
Specifically,
<Redacted B4> Systen A. W e obse rv ed a leaking diaphragm v alve after the final <Re dacted B4> st ep on the <Re dacted B4> skid used, <Redacted B4> for all sterile injectab le drugs that contai n <Redacted B4> Ex amples of drugs that contain <Redacted B4> from this system include:
• Ketamine 10% USP. 100 mg/mL, 5 mL, SDV. lot 2602003
• Lidocaine HCl 1 %/Epinephrine Bitartrate 10 mcg/mL Injection USP, 10 mL, SDV, lot 2603001
• Albuterol Sulfate 0.5%, 10 mL, lot 2512002
• Bupivacaine Hydrochloride 0.5%/Epine phrine Bitartrate 5 mcg/mL Injection 10 mL vial lot 2608001
B.
There is an approximately one-foot-long <Redacted B4> connected to the <Redacted B4> for the <Redacted B4> on the <Redacted B4> System. <Redacted B4> contains a <Redacted B4> from the <Redacted B4> System. ...
Observation 4
Written records are not always made of investigations into unexplained discrepancies.
Specifically
Particulate Matter
A.
Production processes, procedures, and equipment do not adequately exclude particulates and other potential contaminants from sterile injectable and oral inhalation drug product vials. I reviewed the two most recent <Redacted B4> reports for Trending of Visible Particle at Visual Inspection. The trend reports include result from 100% visual inspection ruled AQL inspection of finished sterile drug vials.
a.
PROT.GSP.0025, Visible Particle Trending August-Dec 2025, approved 02/03/26, documents personnel found visible particulates in multiple vials from all <Redacted B4> batches manufactured and inspected during the review period. The number of vials rejected for particulate matter ranged from <Redacted B4> (0.03%) to <Redacted B4> (0.46%) vials in batches that were released.
b.
PROT.GSP.0035, Visible Particle Trending January 2026-June 2026, approved 08/18/26, documents personnel found visible particulates in at least one vial from all <Redacted B4> batches manufactured and inspected during the review period. ...
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assume that components and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
Growth Media
A.
QC microbiology personnel use Standard Methods <Redacted B4> (Plate Count <Redacted B4> for all <Redacted B4> bioburden samples. There is inadequate justification to use this high <Redacted B4> instead of <Redacted B4> designed to recover microorganisms from low <Redacted B4> <Redacted B4> systems. Growth promotion on the manufacturer COA for Plate Count <Redacted B4> only lists Staphylococcus aureus, Escerichia coli, and Enterococcus faecalis. It does not include waterborne pathogenic microorganisms of interest such as B. cepacia or P. aemginosa that are knwn to colonize high purity <Redacted B4> systems.
B.
The firm accepts Plate Count <Redacted B4> plates based on manufacturer COA and does not perform growth promotion before use.
Nitrogen ...
Inspection May 14, 2025 to May 23, 2025: 5 observations
- Firm on the cover
- Tailstorm Health, Inc. dba Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226-4472
- FEI number
- 3015929581
- Establishment type on the cover
- outsourcing facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087 ) Denver, CO 8 0225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient.
Specifically, your firm's batch records document significant environmental monitoring excursions during filling ofsterile drugs.
A) Nonviable particulate counter (NVPC) data for five of six lots we reviewed of the <Redacted B4> total lots that were manufactured in 2025 using the new ISO 5 <Redacted B4> filling line indicate numerous action limit results occurred during filling, but your quality unit did not document a thorough investigation. For example, the following five batches were released and the first four listed were distributed:
• Bupivacaine HCI 0.5%/Epinephrine Bitartrate 5 mcg/mL Injection, 10 mL, lot <Redacted B4> had approximately 73 action limit results for <Redacted B4> particles and approximately 104 action limit results for <Redacted B4> particles. The maximum result for a <Redacted B4> was 39,258 particles/m3 and the maximum result for a <Redacted B4> was 1,237 particles/m3 .
• Ketarnine 1 % 10 mg/mL, 5 mL (SDV), lot <Redacted B4> particles and approximately 3 action limit results for <Redacted B4> particles. ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
(This is a repeat observation.) Specifically, OOS investigations did not always contain complete written justification to support the root cause and conclusions, and investigations were not always expanded to additional lots when implicated by the root cause.
A) Investigations OOS.23.015 (lot <Redacted B4> 00S.24.001 (lot <Redacted B4>, and OOS.23.016 (lot <Redacted B4> identified sample handling and preparation at your contract laboratory as the probable root cause for OOS liquid particle count results in finished drug lots but did not include specific actions by analysts that might have caused the OOS. The contract laboratory investigation did not find any laboratory errors. There was no thorough explanation of the discrepancy between your investigation and your contract laboratory's investigation. There was no record of remedial action at your contract laboratory to prevent reoccurrence of the unspecified root cause. ...
Observation 3
Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release.
(This is a repeat observation.) Specifically, we observed multiple deficiencies when we examined your firm's visual inspection, AQL, and particle identification procedures, processes, and executed records.
A) Your firm did not determine the identity, source, and route of contamination for particles and fibers observed inside sterile finished drug vials during 100% visual inspection and AQL performed <Redacted B4> for lots we examined. The lots met acceptance criteria for VI and AQL and were released with no additional investigation. For example,
• Inspectors identified 83 units with particles and 16 units with fibers during 100% visual inspection of Sterile Water for Injection, USP 10 mL, lot <Redacted B4>
• Inspectors identified 21 units with particles and eight units with fibers during 100% visual inspection of Bupivacaine HCI 0.5%/Epinephrine Bitartrate 5 mcg/mL Injection, 10 mL, lot <Redacted B4> ...
Observation 4
Routine inspection and checking of equipment is not performed according to a written program designed to assure proper performance.
Specifically, we observed the <Redacted B4> unit on your <Redacted B4> leaking and creating a puddle on the floor on 05/14/25. There were no records available to determine how long this leak was present. Your firm uses <Redacted B4> to produce approximately <Redacted B4> different <Redacted B4> injectable drugs. Examples of lots produced with <Redacted B4> include: Sterile Water for Injection, USP 10 mL, lot <Redacted B4> Bupivacaine HCl 0.5%/Epinephrine Bitartrate 5 mcg/mL Injection, 10 mL, lot <Redacted B4> Ketamine 10% 100 mg/mL, 5 mL (MDV), lot <Redacted B4> and Bupivacaine HCI Injection USP 0.25%, 10 mL, lot <Redacted B4>
Observation 5
Buildings used in the manufacturing, processing and packing of a drug product are not maintained in a good state of repair.
Specifically, we observed maintenance deficiencies with the cleanrooms production technicians use to manufacture all <Redacted B4> injectable drugs including: Sterile Water for Injection, USP 10 mL, lot <Redacted B4> Bupivacaine HCI 0.5%/Epinephrine Bitartrate 5 mcg/mL Injection, 10 mL, lot <Redacted B4> Ketamine 10% 100 mg/mL, 5 mL (MDV), lot <Redacted B4> and Bupivacaine HCl Injection USP 0.25%, 10 m L, lot <Redacted B4>
A) We observed multiple pieces of apparent <Redacted B4> tape under the conveyor belt and on the wall surrounding the outlet from the sealing and capping station of the ISO 5 <Redacted B4> filling line into the ISO 7 <Redacted B4> room. There was no written explanation of why the tape was present or how long it was present.
B)
We observed a missing electrical outlet cover in the ISO 7 <Redacted B4> room with an apparent black substance surrounding the entire outlet. There was no written explanation of how long the outlet cover was missing or the identity of the black substance.
Inspection Jul 7, 2021 to Jul 21, 2021: 4 observations
- Firm on the cover
- TAILSTORM HEALTH INC, 158 S Kyrene Rd, Chandler, AZ 85226
- FEI number
- 3015929581
- Establishment type on the cover
- Outsourcer 503B
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
For example:
a) Visual inspection results of filled vials were found to contain extraneous unidentified visible materials (particles and fibers) during 100% visual inspection processes, but no investigation was opened to identify the foreign materials, determine root cause as to how visible substances are found in a drug that is [( <Redacted B4>) and containerized/filled in a HEPA filtered (ISO 5) environment, and prevent recurrence. For example, the following lots were found with some vials containing foreign substances:
i) Ketamine HCL Injection Lot <Redacted B4> found 5 vials with white particles and 3 vials with glass particles in December 2020.
ii) Calcium Chloride Injection Lot <Redacted B4> found 49 vials containing glass particles, 143 vials with white particles, and 33 vials with fibers in November 2020.
iii) Lidocaine HCL Injection Lot <Redacted B4> found 3 vials with fibers and one vial with a particle in March 2021. ...
Observation 2
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
a) When there is no scientific basis found for invalidating initial out-of-specification {OOS) test results and no assignable cause for the OOS is determined, procedures (SOP.CH.0002 Investigating Out-of-Specification Test Results) allow re-testing, which permits reporting <Redacted B4> additional analyses that meet specifications, averaged, as the final result. Procedures in section 4.5.7.1.4. read in part, "If the investigation cannot determine any readily identifiable sources of analyst error and cannot invalidate the original result the following retest methodology should be implemented:" And continues in section 4.5.7.1.4.4. "Based on this analysis, the original sample can either be confirmed as OOS or rejected." [See Observation 1 concerning retesting] ...
Observation 3
Equipment for adequate control over micro-organisms is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.
a)
< Red acted B4> media plates used for detecting microbes (in ISO 5 RABS area during filling) utilizing passive air sampling methods (settle plates) do not contain neutralizing agents to ensure detection and growth of microbes in the presence of disinfecting agents in the filling room .
b) Procedures for use of settle plates in viable air monitoring and control in the RABS filling area do not include limits for duration of exposure (e.g., less than <Redacted B4> to avoid drying) to ensure that media used is growth supporting. Plates may get exposed during filling up to <Redacted B4> without replacement.
Observation 4
The container labels of your outsourcing facility's drug products are deficient.
The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(lO)(B). Specifically, the container from which the individual units of the drug are removed for dispensing or for administration shall include:
a. Route of administration
Examples of drug product containers that do not contain this information:
• Lidocaine 4% (200mg/5mL) 5mL HCl injection, Lidocaine 1 % (lOOmg/mL) lOmL HCl injection, and Lidocaine 2% (200mg/10mL) lOmL HCl injection
GLP-1 records in this index
The same legal name appears in 1 GLP-1 warning letter and 0 GLP-1 recall reports in this index. See the Tailstorm Health Inc. dba Medivant Health record page.
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Apr 8, 2025 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | Close-out letter, Apr 14, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
The Tailstorm Health Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 11 products naming semaglutide and tirzepatide under the labeler name “Tailstorm Health INC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (11). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 81483-0045 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .25 mg/.05 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0046 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | .5 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0047 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0048 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 1.7 mg/.22 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0049 | SEMAGLUTIDE | SEMAGLUTIDE | INJECTION | SUBCUTANEOUS | 2.4 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0050 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 2.4 mg/.1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0051 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 5 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0052 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 7.5 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0053 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 10 mg/.2 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0054 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 12.5 mg/.25 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
| 81483-0055 | Tirzepatide | Tirzepatide | INJECTION | SUBCUTANEOUS | 15 mg/.3 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA warning letter, Apr 8, 2025
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.